Decrease of the atrial fibrillatory rate, increased organization of the atrial rhythm and termination of atrial fibrillation by AZD7009

J Electrocardiol. Jan-Feb 2013;46(1):29-35. doi: 10.1016/j.jelectrocard.2012.09.002. Epub 2012 Dec 6.

Abstract

Background: The atrial fibrillatory rate (AFR), on AZD7009 as compared to placebo, was investigated as a potential biomarker for electrophysiological effect in early antiarrhythmic drug development.

Methods: Patients with permanent AF received infusions of AZD7009 and placebo in an exploratory two-way, single-blind, randomized cross-over study. The ECG was continuously recorded, and following QRST cancellation the AFR, its standard deviation (SD), the exponential decay and the atrial electrogram amplitude were determined as 3-min averages.

Results: The mean AFR rapidly decreased by 43% from baseline (394 ± 38 to 225 ± 61 fibrillations/min, p=0.0003) on AZD7009, but not on placebo. The SD of the AFR and the exponential decay decreased in parallel. In 2 of 8 patients, termination of AF occurred after the AFR had decreased by 58% and 53%, respectively.

Conclusions: The AFR may potentially serve as a biomarker of electrophysiological effects in early evaluation of rhythm control agents.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Arrhythmia Agents / therapeutic use
  • Atrial Fibrillation / diagnosis
  • Atrial Fibrillation / drug therapy*
  • Atrial Fibrillation / physiopathology*
  • Electrocardiography / drug effects*
  • Female
  • Heart Atria / drug effects
  • Heart Atria / physiopathology*
  • Heart Conduction System / drug effects
  • Heart Conduction System / physiopathology*
  • Heart Rate / drug effects*
  • Humans
  • Male
  • Middle Aged
  • Organic Chemicals / therapeutic use*
  • Placebo Effect
  • Single-Blind Method
  • Treatment Outcome

Substances

  • AZD 7009
  • Anti-Arrhythmia Agents
  • Organic Chemicals